MYD88 L265P Mutation Detection by PCR, Quantitative
2009318
 
Ordering Recommendation
• Useful in distinguishing lymphoplasmacytic lymphoma (LPL) from other low-grade B-cell lymphoproliferative disorders which may be in the differential diagnosis.
• Use when monitoring patients with LPL diagnosis and previously identified MYD88 L265P mutation.
Mnemonic
MYD88
Methodology
Real-time Polymerase Chain Reaction
Performed
DNA isolation: Sun-Sat
Testing: Varies
Reported
7-10 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) OR bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood. (Min: 1 mL) OR Transport 3 mL bone marrow. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum, plasma, FFPE tissue blocks/slides, or frozen tissue. Specimens collected in anticoagulants other than EDTA. Clotted or severely hemolyzed specimens.  
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
CPT Code(s)
81479
Components
Component Test Code*Component Chart Name
2009319MYD88 Source
2009320MYD88 L265P Detection, Result
2009321MYD88 L265P Detection, Quant
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • Lymphoplasmacytic lymphoma
  • Waldenstrom macroglobulinemia